Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tezspire | tezepelumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ozurdex | dexamethasone intravitreal implant | Diabetic macular edema | Do not reimburse | Complete | ||
| Zeposia | ozanimod | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Wakix | pitolisant hydrochloride | Narcolepsy | Do not reimburse | Complete | ||
| Ferriprox | deferiprone | Transfusional iron overload | Reimburse with clinical criteria and/or conditions | Complete | ||
| Dupixent | dupilumab | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Beovu | brolucizumab | Diabetic macular edema | Reimburse with clinical criteria and/or conditions | Complete | ||
| Benlysta | belimumab | Lupus nephritis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyepti | eptinezumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 9, 2024